Application of phlegm-heat clearing capsule in fibroblast migration inhibitor
By using the pharmaceutical composition of Tanreqing Capsules, fibroblast migration is inhibited, and the problem of unseen use in the prior art is solved, scar formation is significantly reduced, and related pathological conditions are prevented.
Patent Information
- Application Number
- CN202310666135.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-06
- Publication Date
- 2024-12-06
AI Technical Summary
There are no reports on the use of Tanreqing Capsules as an inhibitor of fibroblast migration in the prior art, resulting in the irreversible scarring process.
Provided is a pharmaceutical composition comprising Tanreqing Capsules for inhibiting fibroblast migration. The raw materials include scutellaria baicalensis, bear bile powder, goat horns, honeysuckle and forsythia, and can inhibit TGF-β1-induced fibroblast migration. and activation.
Significantly inhibit fibroblast migration, prevent and treat pathological conditions in mammals, including activation of fibroblasts or myofibroblast-related pathological conditions, and reduce scarring.
Smart Images

Figure CN119074807A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of medicines, and in particular to use of Tanreqing capsules as a fibroblast migration inhibitor. Background Art
[0002] The organ injury repair stage is divided into four stages, namely homeostasis / coagulation, inflammatory cell recruitment, proliferation and maturation. In the proliferation stage, fibroblasts are activated and transformed into myofibroblasts, migration increases, and extracellular matrix deposition increases. Excessive collagen synthesis or abnormal collagen turnover and excessive extracellular matrix deposition can accumulate at the site of injury, leading to scarring. This scar formation process leads to irreversible degeneration.
[0003] There is no related report on the use of Tanreqing Capsule as a fibroblast migration inhibitor in the prior art. Summary of the invention
[0004] Based on this, the present invention provides a use of Tanreqing Capsule in the preparation of a fibroblast migration inhibitor.
[0005] According to another aspect of the present invention, there is provided a use of Tanreqing Capsule in preparing a medicament for preventing and treating a pathological condition in a mammal, wherein the pathological condition involves activated fibroblasts or myofibroblasts.
[0006] According to another aspect of the present invention, there is provided a use of a pharmaceutical composition comprising Tanreqing Capsule for a fibroblast migration inhibitor.
[0007] According to another aspect of the present invention, there is provided a use of a pharmaceutical composition comprising Tanreqing Capsules in the preparation of a medicament for preventing and treating a pathological condition in a mammal, wherein activated fibroblasts or myofibroblasts are involved in the pathological condition.
[0008] Furthermore, the Tanreqing capsule can inhibit the migration of fibroblasts.
[0009] Furthermore, the fibroblasts are embryonic fibroblasts.
[0010] Furthermore, the fibroblasts are in vitro fibroblasts.
[0011] Furthermore, the cell pharmaceutical concentration of the Tanreqing capsule is 25 μg / mL to 100 μg / mL.
[0012] Furthermore, the cell pharmaceutical concentration of the Tanreqing capsule is 50 μg / mL to 100 μg / mL.
[0013] Furthermore, the fibroblasts are human fibroblasts or mouse fibroblasts.
[0014] Furthermore, the Tanreqing capsule inhibits the migration and / or activation of the fibroblasts induced by TGF-β1.
[0015] Furthermore, the Tanreqing capsule inhibits scarring.
[0016] Furthermore, the raw materials of the Tanreqing capsule include: scutellaria baicalensis, bear bile powder, goat horn, honeysuckle and forsythia.
[0017] Furthermore, the pharmaceutical composition further comprises one or more drugs and / or extracts for fibroblast migration inhibitors.
[0018] Furthermore, the drug is SB431542 or 4-AP.
[0019] Beneficial effects of the present invention:
[0020] The present invention finds through research that Tanreqing capsules at different concentrations can significantly inhibit the migration of fibroblasts. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without exceeding the scope of protection required by the present invention.
[0022] Figure 1 This is a schematic diagram of the effect of Tanreqing Capsule on the viability of NIH-3T3 and MRC-5 cells, where the unit of the ordinate is %.
[0023] Figure 2 This is a schematic diagram of the results of Tanreqing Capsule inhibiting the migration of NIH-3T3 fibroblasts (100×) (n=4), where the unit of the ordinate is %.
[0024] Figure 3 This is a schematic diagram of the results of Tanreqing Capsule inhibiting the migration of MRC-5 fibroblasts (100×) (n=4), where the unit of the ordinate is %. DETAILED DESCRIPTION
[0025] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work are within the scope of protection of the present invention.
[0026] Unless otherwise indicated, all technical and scientific terms and abbreviations used herein have the meanings commonly understood by those of ordinary skill in the field of the invention or the field in which the terms are used. Although any methods, conditions, substances or materials similar to or equivalent to those disclosed herein may be used in the practice of the present invention, preferred methods, conditions, substances or materials are described herein.
[0027] The present invention is intended to encompass all alternatives, variations and equivalents that may be included in the present invention as defined by the claims. Those skilled in the art will recognize many methods and materials similar or equivalent to those described herein that can be used in the practice of the present invention. The present invention is in no way limited to the methods and materials described.
[0028] As used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0029] In the present invention, the term "comprising" is synonymous with "including". As used herein, the terms "comprising", "including", "having", "containing" or any other variation thereof are intended to cover a non-exclusive inclusion. For example, a composition, process, method, article, or apparatus comprising the listed elements is not necessarily limited to only those elements, but may include other elements not expressly listed or inherent to such composition, process, method, article, or apparatus.
[0030] As described in the background technology section, there is no report on the use of Tanreqing capsule for fibroblast migration inhibitor in the prior art. In order to solve the above problem, the present invention provides a use of Tanreqing capsule in the preparation of a fibroblast migration inhibitor.
[0031] According to another aspect of the present invention, there is provided a use of Tanreqing Capsule in preparing a medicament for preventing and treating a pathological condition in a mammal, wherein the pathological condition involves activated fibroblasts or myofibroblasts.
[0032] According to another aspect of the present invention, there is provided a use of a pharmaceutical composition comprising Tanreqing Capsule for a fibroblast migration inhibitor.
[0033] According to another aspect of the present invention, there is provided a use of a pharmaceutical composition comprising Tanreqing Capsules in the preparation of a medicament for preventing and treating a pathological condition in a mammal, wherein activated fibroblasts or myofibroblasts are involved in the pathological condition.
[0034] In a preferred embodiment, the Tanreqing capsule can inhibit the migration of fibroblasts.
[0035] In a preferred embodiment, the fibroblasts are embryonic fibroblasts.
[0036] In a preferred embodiment, the fibroblasts are in vitro fibroblasts.
[0037] In a preferred embodiment, the cell pharmaceutical concentration of the Tanreqing capsule is 25 μg / mL to 100 μg / mL.
[0038] In the present invention, when concentration or other values or parameters are expressed as ranges, preferred ranges, or a series of upper preferred values and lower preferred values, this should be understood as specifically disclosing all ranges formed by any pairing of any range upper limit or preferred value with any range lower limit or preferred value, regardless of whether the range is disclosed separately. For example, when the range "25-100" is disclosed, the described range should be interpreted as including the range "25-100", "25-90", "25-80", "25-70", "25-60", "25-50", "25-40", "25-30", etc. When a numerical range is described in this article, unless otherwise stated, the range is intended to include its end values and all integers and fractions within the range.
[0039] In a preferred embodiment, the cell pharmaceutical concentration of the Tanreqing capsule is 50 μg / mL to 100 μg / mL.
[0040] In a preferred embodiment, the fibroblasts are human fibroblasts or mouse fibroblasts.
[0041] In a preferred embodiment, the Tanreqing capsule inhibits the migration and / or activation of the fibroblasts induced by TGF-β1.
[0042] In a preferred embodiment, the Tanreqing capsule inhibits scarring.
[0043] In a preferred embodiment, the raw materials of the Tanreqing capsule include: scutellaria baicalensis, bear bile powder, goat horn, honeysuckle and forsythia.
[0044] In a preferred embodiment, the pharmaceutical composition further comprises one or more drugs and / or extracts for fibroblast migration inhibitors.
[0045] In a preferred embodiment, the drug is SB431542 or 4-AP.
[0046] The SB-431542 of the present invention is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 can inhibit TGF-β-induced transcription, gene expression, cell apoptosis and growth inhibition. SB-431542 can be used for the study of cancer and its signal transduction pathways. The 4-AP of the present invention is a specific blocker of type A potassium ion channels. Compared with other types of potassium channel blockers, it has a stronger inhibitory effect on the migration activity of fibroblasts induced by TGF-β1.
[0047] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually carried out according to conventional conditions or conditions recommended by the manufacturer.
[0048] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only.
[0049] The above features mentioned in the present invention or the features mentioned in the embodiments can be combined in any way. All the features disclosed in this patent specification can be used in combination with any combination form, and each feature disclosed in the specification can be replaced by any alternative feature that can provide the same, equal or similar purpose. Therefore, unless otherwise specified, the disclosed features are only general examples of equal or similar features.
[0050] Example
[0051] 1. Experimental Materials
[0052] MRC-5 and NIH-3T3 were gifts from Nankai University.
[0053] Table 1 Experimental reagents
[0054]
[0055]
[0056] 2. Experimental Instruments
[0057] Table 2 Experimental instruments
[0058] Instrument Name Manufacturer Thermo CO2 Incubator Thermo Company of Germany HR 40-IIA2 Biological Safety Cabinet Qingdao Haier Co., Ltd. Leica Inverted Fluorescence Microscope Leica, Germany DYML-S50A3 High Pressure Steam Sterilization Northern Qincheng Shengda Science Co., Ltd. EL-220A Electronic Balance Changzhou Tianzhiping Co., Ltd. XS-205DU 100,000th Balance Mettler Toledo, Switzerland Seven Easy S20 Benchtop pH Meter Mettler Toledo, Switzerland Elix / Rio Ultrapure Water Purification System Millipore Corporation Flexstation3 Multi-function Microplate Reader Molecular Devices Operetta High Content Screening System Platinum Elmer Co., Ltd. KO-250E Ultrasonic Cleaner Kunshan Ultrasonic Instrument Co., Ltd. SW-CJ-1F Clean Bench Tianjin Southeast Yicheng Technology Co., Ltd.
[0059] 3. Experimental Methods
[0060] 3.1 Cultivation of NIH-3T3 and MRC-5
[0061] NIH-3T3 cells were cultured in a complete medium containing 10% FBS, penicillin (100 U / mL) and streptomycin (100 mg / mL) in a 37°C, 5% CO2 constant temperature cell culture incubator. When the cell fusion reached about 80%, the cells were passaged.
[0062] MRC-5 cells were cultured in MEM medium (containing non-essential amino acids) containing 10% Cha serum, penicillin (100 U / mL) and streptomycin (100 mg / mL) in a 37°C, 5% CO2 constant temperature cell culture incubator. When the cells were about 80% confluent, they were passaged.
[0063] 3.2 CCK-8 (Cell Counting Kit-8) method to detect cell viability
[0064] NIH-3T3 cells grown to the logarithmic phase were inoculated into 96-well cell culture plates with an inoculation density of 7,000 cells per well. The drug concentration of Tanreqing Capsule was set at 5 gradients, namely 200 μg / mL, 100 μg / mL, 50 μg / mL, 25 μg / mL, and 10 μg / mL. 4-6 replicate wells were set up respectively. The cells were incubated with different concentrations of Tanreqing for 48 hours. After discarding the supernatant, each well was washed with sterile PBS, and 10 μL of CCK-8 solution was added respectively. The wells were incubated in a cell culture incubator for 1-4 hours, and the absorbance of each well at 450 nm was measured by an enzyme marker.
[0065] The experimental contents of MRC-5 are the same as those of NIH-3T3.
[0066] 3.3 Fibroblast scratch assay
[0067] Draw three straight lines on the back of a 24-well cell culture plate in advance, with an interval of 0.5 to 1 cm. NIH-3T3 and MRC-5 cells in the logarithmic growth phase were inoculated in a 24-well plate with a label. After attachment, they were synchronized with 0.5% fetal bovine serum medium for 12 hours. After synchronization, a 200 μL pipette tip was used to draw a line perpendicular to the pre-drawn straight line, and the supernatant and scratch area were discarded. Then, the detached cells were washed with PBS. The drug groups were: control group (Control), different concentrations of TRQ (25, 50 and 100 μg / mL), SB431542 (5 μM) and TGF-β1 (5 ng / mL) were used to treat the cells. Photos of the migration area were taken at 0, 24 and 48 hours after administration. The image software Fiji-ImageJ was used to calculate the size of the cell migration area.
[0068] 4. Experimental Results
[0069] 4.1 Effect of Tanreqing Capsule on the Viability of Mouse and Human Fibroblasts
[0070] In order to explore the safe dosage of TRQ in in vitro experiments, this experiment used two cell lines from different sources to detect cell viability after administration.
[0071] like Figure 1 As shown, TRQ at a concentration of 100 μg / mL had an in vitro and in vivo effect on mouse embryonic fibroblasts NIH-3T3 ( Figure 1 A) and human embryonic lung fibroblasts MRC-5 ( Figure 1 B) There was no effect on cell viability, but it inhibited cell viability when the concentration was greater than 100 μg / mL. Therefore, the subsequent administration used a concentration below 100 μg / mL as a safe dosage.
[0072] 4.2 Effect of Tanreqing Capsule on the Migration of Mouse and Human Fibroblasts
[0073] like Figure 2 and Figure 3 As shown, the cell migration experiment showed that TRQ at a concentration of 25 μg / mL significantly inhibited the migration of NIH-3T3 cells (P<0.001); similarly, similar results were found in MRC-5 cells, and TRQ at a concentration of 50 μg / mL significantly inhibited the migration of fibroblasts (P<0.01).
[0074] The embodiments of the present invention are described in detail above. Specific examples are used herein to illustrate the principles and implementation methods of the present invention. The description of the above embodiments is only used to help understand the method of the present invention and its core idea. At the same time, changes or deformations made by those skilled in the art based on the ideas of the present invention, the specific implementation methods and application scope of the present invention, all belong to the scope of protection of the present invention. In summary, the content of this specification should not be understood as limiting the present invention.
Claims
1. A method for preparing a Tanreqing capsule for use as a fibroblast migration inhibitor.
2. Use of Tanreqing Capsule in the preparation of a medicament for preventing and treating a pathological condition in a mammal, wherein the pathological condition involves activated fibroblasts or myofibroblasts.
3. Use of a pharmaceutical composition comprising Tanreqing Capsule for a fibroblast migration inhibitor.
4. Use of a pharmaceutical composition comprising Tanreqing Capsules in the preparation of a medicament for preventing and treating a pathological condition in a mammal, wherein activated fibroblasts or myofibroblasts are involved in the pathological condition.
5. The use according to any one of claims 1 to 4, characterized in that The Tanreqing capsule can inhibit fibroblast migration; Preferably, the fibroblasts are embryonic fibroblasts; More preferably, the fibroblasts are in vitro fibroblasts; Preferably, the cell pharmaceutical concentration of the Tanreqing capsule is 25 μg / mL to 100 μg / mL; Particularly preferably, the cell pharmaceutical concentration of the Tanreqing capsule is 50 μg / mL to 100 μg / mL.
6. The use according to any one of claims 1 to 4, characterized in that The fibroblasts are human fibroblasts or mouse fibroblasts.
7. The use according to any one of claims 1 to 4, characterized in that The Tanreqing capsule inhibits the migration and / or activation of the fibroblasts induced by TGF-β1.
8. The use according to any one of claims 1 to 4, characterized in that The Tanreqing capsule inhibits scarring.
9. The use according to any one of claims 1 to 4, characterized in that The raw materials of the Tanreqing capsule include: scutellaria baicalensis, bear bile powder, goat horn, honeysuckle and forsythia.
10. The use according to claim 3 or 4, characterized in that: The pharmaceutical composition further comprises one or more drugs and / or extracts for fibroblast migration inhibitors; Preferably, the drug is SB431542 or 4-AP.
